Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting

Core Insights - Monopar Therapeutics Inc. announced new data on the long-term neurological efficacy and safety of its investigational therapy ALXN1840 for Wilson disease, to be presented at the 150th American Neurological Association Annual Meeting [1][3] - The analysis pooled efficacy outcomes from three independent clinical trials involving 255 patients, while safety data included a fourth independent clinical trial with 266 patients, with a median treatment duration of approximately 2.6 years [2] Efficacy and Safety Findings - Long-term neurological benefits of ALXN1840 were highlighted, showing sustained improvement on the Unified Wilson Disease Rating Scale (UWDRS) over 6 years [6] - Patients who switched from standard of care to ALXN1840 experienced additional neurological improvements, with many reversing previous declines [6] - Statistically significant psychiatric improvements were also sustained over multiple years, measured by the Brief Psychiatric Rating Scale (BPRS) [6] - Neurological benefits were consistently observed across multiple independent studies [6] - The safety profile of ALXN1840 was favorable, with less than 1% of patients experiencing drug-related serious adverse events over more than 645 patient-years [6] Company Overview - Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for unmet medical needs, including ALXN1840 for Wilson disease and various radiopharmaceutical programs [4]